Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
347 Leser
Artikel bewerten:
(2)

MDBriefCase Announces Relaunch of RxBriefCase, a Leading Continuing Education Platform for Pharmacists

TORONTO, ON / ACCESSWIRE / September 25, 2024 / MDBriefCase, a leading provider of interactive accredited continuing medical education for healthcare professionals, is proud to announce the upcoming relaunch of RxBriefCase in partnership with Pharmapod, the top medication safety reporting platform for pharmacists.

Launching in early 2025, RxBriefCase will offer a comprehensive range of accredited on-demand pharmacy courses designed to keep pharmacists' skills sharp and current in an evolving healthcare landscape.

RxBriefCase courses will cover a diverse array of topics, including patient safety, travel medicine, medication management, and infectious disease, ensuring that pharmacists have access to the latest professional development resources. The platform's relaunch highlights MDBriefCase's commitment to excellence in clinical education and support for healthcare professionals.

Sachin Aggarwal, CEO of Think Research, said, "Our goal is to empower pharmacists with the tools and knowledge they need to excel in their roles and provide exceptional patient care. RxBriefCase will serve as a trusted resource for ongoing professional development, helping pharmacists stay informed about the latest advancements in the field."

Janet Kimura, Managing Director & EVP, Clinical Content and Education at MDBriefCase, added, "We are thrilled to bring RxBriefCase back with enhanced content and features that align with the needs of today's pharmacists. Our team is dedicated to curating high-quality educational experiences that support pharmacists in their lifelong learning journeys."

Brynne Eaton-Auva'a, Managing Director, Clinical Connectivity, said, "We're incredibly proud to relaunch RxBriefCase in partnership with Pharmapod, combining our educational expertise with leadership in patient safety. This collaboration will bring educational resources to Pharmapod users and represents a major step forward in empowering pharmacists with cutting-edge knowledge while supporting the highest standards of care. Our aim is to make pharmacy safety and professional development as accessible, relevant, and impactful as possible for today's pharmacists."

Pharmacists can look forward to an engaging, user-friendly platform designed to fit seamlessly into their busy schedules, offering flexibility and convenience in accessing crucial educational resources.

In collaboration with Pharmapod, the leading platform for pharmacy safety, courses will also be accessible directly through Pharmapod, enhancing the user experience by integrating continuing education with quality improvement solutions.

RxBriefCase is scheduled to relaunch in early 2025. Join our mailing list to be notified when the site is live. Join list here: https://www.mdbriefcase.com/rxbriefcase-update/

For more information, contact Janet Kimura janet.kimura@mdbriefcase.com.

About MDBriefCase

MDBriefCase, a Think Research subsidiary, is a leading provider of accredited, online continuing professional development (CPD) to help healthcare practitioners enhance their professional practice and stay at the forefront of the latest evidence and protocols. Through innovative partnerships, we offer high-quality content, free of charge, to more than 280,000 members in Canada, Australia, Africa and the Middle East. More information at mdbriefcase.com.

About Pharmapod

Pharmapod is the leading cloud-based continuing quality improvement (CQI) solution for driving efficiencies and reducing patient safety incidents in community pharmacies, long-term care, and hospitals. Built by pharmacists for pharmacists, our technology is chosen globally by industry leaders, regulators, academic sites and national healthcare providers, including 70% of pharmacies in Canada, to drive excellence in medication safety and promote data-driven innovation, safety and quality improvements. More information at pharmapodhq.com.

RxBriefCase, MDBriefCase and Pharmapod are members of the Think Research family of companies.

SOURCE: MDBriefCase

© 2024 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.